Review Article

Inclisiran - A New Therapeutic Drug in Treating Hypercholesterolemia

P. Kishore Kumar[1]*, K. Malikarjun Rao[1], Bagadam Aparna[1], Syed Mohiuddin Quadri[1], V. Uma Maheshwara Rao[2]
1*. M. Pharm. Ph.D. Associate Professor, Dept. of Pharmacology, CMR College of Pharmacy, Medchal, Hyderabad, India
1. Student, Department of Pharm D, CMR College of Pharmacy, Medchal, Hyderabad, India
2. M. Pharm. Ph.D. Principal, CMR College of Pharmacy, Medchal, Hyderabad, India
***Corresponding author's E-mail:** Kishorekumarpasupuleti189@gmail.com

Received: 14-05-2026; **Revised:** 26-07-2026; **Accepted:** 03-08-2026; **Published online:** 20-08-2026.

ABSTRACT

Background: One of the most prominent preventable factors contributing to cardiovascular morbidity and mortality around the world, hypercholesterolemia is widely recognised as a major contributor to atherosclerosis. Vascular inflammation, buildup of plaque, and dysfunction of endothelial cells are all enhanced by persistently elevated LDL cholesterol. Although statins serve as the foundation of treatment, a substantial number of patients either experience intolerance or fail to achieve their target LDL-C levels, emphasising the need for complementary methods of therapy.

Methodology: The epidemiology, pathology, and therapeutic management of hypercholesterolemia are outlined in this article. The role of PCSK9's regulatory impact on LDL receptor degradation and hereditary and acquired variations of the disease was examined. A thorough investigation was carried out on the existing clinical and pharmacological information regarding inclisiran, an innovative small interfering RNA that targets PCSK9.

Results: By specifically degrading PCSK9 mRNA, inclisiran reduces hepatic PCSK9 production, enhancing the availability of receptors for LDL and promoting the removal of circulating LDL-C. Clinical trials consistently demonstrate a nearly 50% persistent reduction in LDL-C through a simple twice-yearly dose regimen following initial loading doses. The drug displays favourable pharmacokinetic features, limited systemic exposure, and an adequate safety profile.

Discussion: Compared with conventional lipid-lowering treatments, inclisiran's long-lasting capability could improve treatment adherence. Whereas prolonged outcomes information remains to be obtained, its approach of action offers an apparent advantage in patients who fail to respond effectively to statins.

Conclusion: As a result, Inclisiran reduces LDL-C effectively and consistently with periodic doses, representing a promising development in lipid management. To clarify the impact on cardiovascular outcomes and its availability in various medical settings, further long-term investigation is needed.

Keywords: Hypercholesterolemia, LDL Cholesterol, HDL Cholesterol, PCSK9 gene, Interfering RNA.

INTRODUCTION

Ischemic heart disease and stroke are the most prevalent kinds of cardiovascular diseases (CVDs), and they constitute the world's leading cause of fatalities and morbidity[1]. A significant risk indicator for the first signs of atherosclerosis and subsequent cardiovascular events is hypercholesterolemia, and is represented by higher levels of LDL-C [2].

Hypercholesterolemia constitutes one of the main indicators of atherosclerotic. Fortunately, high cholesterol is the tolerant factor that enables other potential risks to function properly [3] . Atherosclerosis can be caused by elevated LDL-C levels, which can additionally induce endothelial dysfunction, the growth of plaque, and enhanced inflammatory responses in the walls of arteries [4].

Cholesterol is a crucial constituent of plasma membrane, where this limits the permeability of tissue layer while maintaining membrane fluidity. Additionally, cholesterol serves as the building block for a variety of physiologically significant steroidal compounds, including bile acids and their conjugates, vitamin D, and sex hormones. Dysregulation of cholesterol homeostasis, therefore, can disrupt multiple cellular processes and set off a series of grave health consequences, including hypercholesterolemia and atherosclerosis [5].

In accordance to guidelines of Joint British Societies (JBS2) to an effort toward preventing cardiovascular disease, patients with pre-existing atherosclerotic disease, diabetes, or fusion of additional determinants will result in 20% or higher risk of heart disease over the next ten years ought to aim for optimal levels of plasma cholesterol (≤4 mmol/l) and LDL cholesterol (≤2 mmol/l). Smoking cigarettes, high blood pressure, inadequate levels of good cholesterol, perched triglycerides, low socioeconomic class constitutes some of these risk factors [3].

TYPES OF LIPOPROTEINS

Specialized particles termed lipoproteins are essential for the bloodstream's lipid transport. Chylomicron, Chylomicron remnants, VLDL, IDL, HDL, LDL, Lp(a) are the different types of lipoproteins, of which Chylomicron is the largest size and least in density lipoprotein with density below 0.930 which then converted into a smaller remnant [6]. VLDL particles are created by the liver and distribute endogenously produced triglycerides to muscle and adipose

tissues [7]. It possess density between 0.930 and 1.006 g/mL. LDL serves as a transitional lipoprotein ahead of being further processed into LDL and gets produced by the metabolism of VLDL [8]. LDL possess density of 1.006–1.019 g/mL, LDL with a density of 1.019–1.063 g/mL, HDL possess smaller density of 1.063–1.210 g/mL and Lp(a) possess even more smaller density of 1.055–1.085 g/ml [6].

Hypercholesterolemia types

Genetics

Familial hypercholesterolemia (FH), a classical genetic disorder, is brought on by modifications to the LDL-receptor, which usually trigger LDL-cholesterol levels found in heterozygotes that exceed 190 mg/dl and in homozygotes that exceed 450 mg/dl [9]. Mutations in genes involving LDLR, APOB, and PCSK9 constitute the primary manifestation of it; these mutations influence the function in the LDL receptors and the elimination of cholesterol[10]. The reason behind a minimum 85% of familial hypercholesterolemia is defect in the low density lipoprotein receptor. Alterations in Encoding the genes of low density lipoprotein receptor causing loss of function have been the reason of hypercholesterolemia. There be a reduction in the rate as to which LDL is eliminated from the bloodstream as a result of reduced liver LDL receptor activity.

Additional inherited sources in FH comprises:

*Apolipoprotein B deficiency, frequently caused by a change in position 3500, that prevents the ligand from binding to the LDL receptor.
*An increase in PCSK9's affinity for the LDL receptor due to obtain a change in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene triggers LDL receptor to be cleared promptly by carrying it to the lysosome for hepatic degradation, thus increasing plasma LDL-C levels [9].

The apolipoprotein B encodes Apo B, which is one of the LDL receptor donor. Hypobetalipoproteinemia caused by majority of the other forms that have been turn up to the central records, which are LOF changes. This has been detected, however, certain kinds of nonsynonymous variants can end up in ADH. These differences are particularly noticeable in the crucial area of APOB gene exon 26. Changes in this area reduce apo B's affinity for LDL receptors, resulting in poor LDL receptor binding [11].

PCSK9 has become at the center of much attention currently as an achievable goal for minimizing patients' LDL-C levels [12].A protein called PCSK9 controls the decomposition of LDL receptors on the superficial of hepatocytes, which within influences deportation of LDL-cholesterol from the blood. That quantity of LDL receptors available for removing LDL-C from the blood is decreased when PCSK9 tie up to LDL receptors and encourages their destruction in lysosome organ. Thus, blocking PCSK9 can increase the expression of LDL receptors and lower LDL-C levels. Currently, the primary goal of PCSK9-targeting drug research and development is to stop PCSK9 from binding to the low-density lipoprotein (LDL) receptor [13].

Acquired

It is acquired as an effect of using drugs like oral contraceptives, beta blockers, corticosteroids, diabetes, nephritic syndrome, and chronic alcoholism. Significant hypertriglyceridemia combined with secondary hyperlipidemia can cause pancreatitis [14].

PATHOPHYSIOLOGY

Hypercholesterolemia is among the most significant risk variables, that contributes in buildup of atherosclerotic plaques. An imbalance between the synthesis of cholesterol, dietary intake, and clearance procedures promotes hypercholesterolemia, resulting elevates plasma cholesterol levels, notably LDL-C. Genetic sensitivity, hepatic cholesterol metabolism, and lipoprotein receptor function constitute a few of the contributing factors that are linked to the pathophysiology of hypercholesterolemia [15].

This raises the possibility of a numerous undesirable clinical results, including CAD, PAD, aortic aneurysms, and stroke. Blood levels of LDL are the principle variable resulting in the greater likelihood for developing atherosclerotic lesions. Furthermore, plenty of studies demonstrate an association between an elevated blood level of HDL, or high-density lipoprotein, and decreased risk. Nevertheless, side effects have been identified in clinical trials including medications which boost HDL cholesterol. Reducing LDL levels therefore becomes vital for patient care [16].

The principal lipoprotein transporters of endogenous cholesterol esters are LDL and HDL; however, they also carry smaller quantities of phospholipids, triglycerides, and fat-soluble vitamins. Low density lipoprotein (LDL) receptors are either completely absent or severely dysfunctional in hypercholesterolemia. The LDL receptor protein has 860 amino acids and is encoded by a gene found on chromosome 19's short arm. It is the main factor influencing the absorption of LDL by the liver, which typically breaks down around 70% of circulating LDL. Apo lipo-proteins, which reside in the lipoprotein lipid outer layer, have an abundance of purposes, such as deciding as cofactors for enzymes and receptors as well as giving lipoproteins their structural foundation. ApoB-100 constitutes one of the LDL apolipoproteins, and Apo A-I, II, IV, V, Apo C-III, and Apo E are among the HDL apolipoproteins. The body uses lipo-proteins for transportation of dietary and hepatic lipids to tissues requiring these substances for energy or storage regarding saturated fats [17]. LDLR is responsible for delivering LDL-C from the circulatory system into the hepatic cells where are subsequently utilized or eliminated. Family-associated hypercholesterolemia is triggered on alterations in the LDLR gene, that increase circulating levels of LDL-C and limit LDL clearance [18]. LDLR turnover is modulated by proprotein convertase subtilisin/kexin type 9 (PCSK9), that accelerates its lysosomal degradation. Elevated total cholesterol levels, reduced LDLR availability, and impoverished LDL-C clearance have all been attributed to increased PCSK9 activity [19].

The complexity of the LDLR's molecular biology is broadly comprehends, basic inquiries about how the receptor conveys its chemical payload beneath cells without infractions apart itself have only more recently been brought into luminescence. A persuasion model of how the receptor binds LDL at the cell membrane with high affinity and then releases it in the proper intracellular compartment is currently presented through the crystal structure of the protein's extracellular domain [13]. The extracellular domain of the LDLR broadens when it is on the cell surface, implementing the ligand-binding domain visible to LDL. The LDL receptors have a greater affinity for apo-E than for apo-B-100, and certain modifications of the receptors may prevent the absorption of LDL by permitting binding to apoE [20]. Highly atherogenic, oxidized LDL (oxLDL) promotes atherosclerosis primarily inducing endothelial dysfunction, macrophage recruitment, and foam cell generation [21]. Chronic inflammation renders abnormal lipid profiles even worse, as seen in diabetes and metabolic syndrome [22].

EPIDEMOLOGY

The Centers for Disease Control and Prevention (CDC) estimate 31.7 percent among adult Americans, as well as a total of 73.5 million people have elevated LDL-C levels, putting them at risk. twice as probable to experience heart disease when compared with those of normal levels. Treatment to lower LDL-C levels is only being received by 48.1% of patients. As explained by recent data, the frequency of occurrence of the classic disorder FH is estimated to be 1/300,000 in the homozygous state and 1/250 in the heterozygote state. It may reach 1/100 in some groups, including Afrikaners, Lebanese, and French Canadians [9].

The WHO last reported the frequency of occurrence of hypercholesterolemia in adults worldwide in 2008, and it is currently 39%. According to a more recent estimate, the prevalence of increased total serum cholesterol is 11.9%, estimates approximately 28.5 a million persons with raised levels among this blood type. Regardless of numerous treatment possibilities, the occurrence of elevated cholesterol has been progressively rising in Singapore over the years [5].

DIAGNOSIS

Lipid profiling, clinical examination, and in particular circumstances, genetic testing are employed to diagnose hypercholesterolemia. Preventing heart disease demands detection promptly [23].

Individuals over 40 oughts to have their plasma lipid profile assessed, usually following nighttime fasting for ten to twelve hours. The lipid panel comprises details regarding HDL cholesterol, triglycerides, and total cholesterol. The Fried Ewald Equation is employed for determining LDL cholesterol.

Total cholesterol – VLDL(TG/5) − HDL-C yields LDL-C.

It is known as Fried Ewald equation, is reliable when the triglyceride level and fasting plasma test results are less than 200mg/dl. If the levels are more than 400mg/dl, it is conventional not to use it because excessive triglycerides modify the VLDL-C. Additionally, there are numerous ways to evaluate LDL-C directly. Tests for TSH (hypothyroidism), glucose (diabetes), bilirubin and alkaline phosphatase (cholestasis), urinalysis and serum albumin (nephrotic syndrome), and glucose (diabetes) can rule out secondary causes. Before initiating future medical care, the test should ideally be performed in a couple of weeks if the findings reveal an abnormal lipid profile (high cholesterol) [23].

The following recommendations for screening:

- Men aged over 35
- over-45 women
- Diabetes type 2
- Use of tobacco
- Cardiovascular disease in the family history
- Personal background of peripheral vascular disease or heart disease
- BMI more than thirty implies obesity.
- High blood pressure [9].

Diagnostic criteria for Hypercholesterolemia

- MEDPED Criteria (United States)
- Simon Broome criteria (United Kingdom)
- Dutch criteria (The Netherlands) [13].

TREATMENT

Treatment for elevated blood cholesterol comprises lifestyle modifications, prescription drugs, and specialized lipid-lowering procedures [24]. HDL-C levels improve and lipid metabolism can be enhanced with aerobic exercise [25]. Since low levels of LDL are the first lipoprotein known to cause atherosclerosis, its detrimental effects on the cardiovascular system, lowering them is anticipated to have this effect. Medication therapy and lifestyle modifications should be initiated solely based on the presence of risk factors, CHD, and high LDL. Treatment for hypercholesterolemia with monotherapy has been shown effective, even so, combined therapy can be necessary for a thorough approach. For the time being, there are 5 main types of antihyperlipidemic drugs: drugs that block the absorption of cholesterol, fibric acids, bile acid sequestrants, HMG CO-A reductase antagonists, and nicotinic acid derivatives [14].

PHARMACOLOGICAL TREATMENT

HMG Co-A reductase inhibitors

Statins or HMG-CoA reductase inhibitors, primarily inhibit HMG-CoA reductase to decrease hepatic cholesterol synthesis, are the backbone of pharmacological treatment [26]. The substrate of (HMG-CoA) reductase is similar to statins. When they attach to the epitope of an enzyme, they alter the structure of the enzyme in addition to functioning

as competent with the usual substrate on the epitope. By this mechanism, A functional structure is prevented from being achieved by HMG CoA reductase. These medications are extremely selective and effective due to a conformational shift at the active site. As a result, the concentration of cholesterol in hepatocytes is reduced [27]. Patients at high cardiovascular risk should consider taking high-intensity statins, such as atorvastatin and rosuvastatin[28].

Bile acid sequestrants

Bile acid sequestrants are the preferred medication in treating hypercholesterolemia. Studies with over time subjects have demonstrated these medications' capacity to reduce the effects of atherosclerosis and slow its progression. To further improve the effects of bile acid sequestrants on cholesterol reduction, they can be used in conjunction with other lipid-lowering medications such as nicotinic acid or HMG CoA reductase inhibitors. Overall, the side effect profile is tolerable [29].

Nicotinic acid derivatives

Nicotinic acid and its derivatives suppress hepatic diacylglycerol acyltransferase-2 (DGAT-2) and hepatic VLDL manufacturing, reducing LDL-C and triglycerides while enhancing HDL-C levels [30]. The matured particle gets released into the plasma, where lipoprotein lipase confined to capillaries delipidates it. Through this process, the liver and peripheral cells absorb the triglyceride fatty acids that VLDL gradually loses from the core and the particle contracts. The LDL component can then be consumed as an outcome of the LDL receptor's activity by hepatocytes or peripheral tissues. Little or adapted LDL can also result from the metabolism of LDL. Reduced hepatic supply of non-esterified fatty acids caused by nicotinic acid action leads to decreased liver triglyceride synthesis, a diminished VLDL triglyceride precursor pool, and a decrease in VLDL secretion, which in turn lowers plasma levels of VLDL and subsequently LDL [31].

Fibric acids

According to the FDA standards, patients with mixed dyslipidemia or primary hypercholesterolemia should be administered fibric acids. Fenofibrate and gemfibrozil were prominent examples of fibric acid derivatives (fibrates), that primarily reduce triglyceride levels and almost enhance HDL-C through activating peroxisome proliferator-activated receptor-alpha (PPAR-α) [32]. Whenever fibric acids bind to PPAR-alpha, they function as ligands. PPAR-alpha is a nuclear receptor family transcriptional factor that is activated through ligands. Once stimulated, PPAR-alpha regulates a number of biological processes, such as lipid metabolism and fatty acid beta-oxidation. Fibric acids lower blood cholesterol by binding to PPAR-alpha, which in turn leads to fatty acid oxidation, the expulsion of particles rich in triglycerides, along with the breakdown of bad cholesterol [33].

Cholesterol absorption inhibitors

The first treatment in an entirely novel category of selective absorption inhibitors of cholesterol is ezetimibe. When administered in along with statins, ezetimibe lowers intestinal cholesterol absorption with an extra 15-20% [34]. It inhibits hepatically excreted biliary cholesterol as well as dietary cholesterol's intestine reabsorption. Ezetimibe is a safe and effective drug that lowers both non-HDL-C and LDL-C [35].

NON-PHARMACOLOGICAL TREATMENT

Diet

A nutritious diet is essential to preventing these fatal ailments. Dietary factors also influence the conventional risk factors such as arterial pressure, dextrose levels, adiposity, and inflammation [9]. Epidemiological research indicates that low-starch vegetables, fruits, nuts, legumes, seafood such as shellfish vegetable oils, and whole grain goods are healthy [2].

Liver transplant

Pharmacological therapies intended for lowering bad cholesterol have a limited effect. Liver transplantation is viewed as to be the only therapy chance for individuals having issues related to hepatic cholesterol metabolism owing to the liver occupies the vast majority of the LDL receptors. Since 1984, frequency of hepatic transplants, including those coupled with heart transplants, has increased for HoFH patients, establishing liver transplantation as a reliable treatment option on a global scale. After transplantation, there is a reported dramatic 80% decline in plasma LDL-C along with a rapid regression of cutaneous and tendinous xanthomas. Long-term cardiovascular benefits are still unknown, though. The requirement for immunosuppressive medication for the rest of a person's life, surgical complications, and liver transplant rejection are the main causes for concern [36].

Gene mediated technology

The functional domain of the predominantly well-maintained CRISPR gene comprises nuclease activity capable of preferentially split DNA sequences. The advantages of this technology over somatic cell edition involve ease of production, reduced costs, and improved effectiveness [37]. In addition to offering solid evidence that gene editing can be utilized for managing increased low-density lipoprotein (LDL) cholesterol, the effective completion of human gene editing trials presents an opportunity for additional research on the effect of gene editing on the risk of atherosclerotic cardiovascular disease in individuals [38].

Lipoprotein apheresis

Lipoprotein apheresis effectively reduces LDL-C and Lp(a) levels in patients with severe hypercholesterolemia, such as patients with homozygous familial hypercholesterolemia (HoFH) [39]. An established extracorporeal technique referred to lipoprotein apheresis (LA) is employed to separate

lipoproteins containing apoB specifically from a patient's plasma [40]. For patients whose bad cholesterol levels have never been brought down toward the desired levels through conventional lipid-lowering medication therapy, it is currently the preferred method of treatment. Previous research has manifested that lipoprotein plasmapheresis is beneficial for lowering bad-C levels and minimizing the number of cardiac events [41].

NEW PHARMACOLOGICAL APPROACH IN TREATING HYPERCHOLESTEROLEMIA - INCLISIRAN

Inclisiran is an innovative siRNA drug that inhibits the production of PCSK9 in the liver's cells via attacking PCSK9 mRNA [42]. Proprotein convertase subtilisin kexin 9 (PCSK9) targeting has become one of the newest and safest approaches to reduce LDL-C levels. The regulation of bad cholesterol processing is significantly impacted under PCSK9. Cell-membrane bad cholesterol receptors are degraded by lysosomal processes owing to this substance, which is generated and modified in the hepatocyte endoplasmic reticulum. PCSK9 binds to the epidermal growth factor after being secreted into plasma. An LDL receptor domain is one of the components that the hepatocyte internalizes. Additionally, evidence suggests the intracellular process is how the PCSK9 protein chaperones the LDL receptor. Instead of returning to the hepatocytic membrane as usually the case, the LDL receptor transfers to the lysosome where it is broken down through the mechanisms of PCSK9 action [43].

Novartis Group developed a novel lipid-lowering medication called Inclisiran. It is the first siRNA medication that has been approved in the management of hypercholesterolemia, combined dyslipidemia, ASCVD, also heterozygous familial hypercholesterolemia (HeFH) patients who require further LDL-C level lowering [13].

Mechanism of action



Figure 1: Flow chart on mechanism of action of drug Inclisiran [6].

[Inclisiran reduces LDL-C levels by silencing PCSK9 mRNA, thereby enhancing LDL receptor recycling and decreasing LDL receptor degradation.]

Inclisiran is a small interfering RNA (siRNA)-based therapy that lowers PCSK9 protein synthesis in hepatocytes by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) at the mRNA level [44]. In accordance with Kosmas et al. (2018), Inclisiran binds selectively to the liver cell membrane's asialoglycoprotein receptor (ASGPR) and n-acetylgalactosamine (GalNAc). ASGPR is a receptor that mediates the endocytosis of glycoproteins in liver cells. GalNAc is a sugar molecule that increases the affinity and specificity of inclisiran for this receptor. It connects itself to

the RNA-induced silencing complex (RISC) once it reaches hepatocytes a protein complex referred to RISC uses the guide strand of siRNA to determine and cleave the target mRNA. Simultaneously, it binds to the mRNA that codes for PCSK9 protein through the antisense chain, leading to a reduction in PCSK9 protein synthesis. The expression of LDL receptors on the liver surface is regulated through protein PCSK9. There are fewer LDL receptors available for removing bad-C from the blood as an outcome of PCSK9's binding to LDL receptors and promotion of their lysosomal degradation. Therefore, Inclisiran can better express LDL receptors and reduce LDL-C levels by reducing PCSK9 production [13].

Pharmacokinetics of Inclisiran

The pharmacokinetic characteristic of inclisiran is unique owing to its small interfering RNA (siRNA) nature, ensuring hepatic absorption and generates long-lasting effects on PCSK9 inhibition [45]. After the end of the use of 60-minute IV injection of medication, the highest possible levels of ALN-PCS is attained. There exists a reasonably linear relationship between the drug dose and both the peak concentration and the area under the drug concentration curve. The greatest decrease in bad-C concentrations took place about 20 days following hypodermic delivery of medication, as per preliminary studies carried out in animal models. The dosage of the medication that was administered did not influence the reduction. The individuals with greater risk of cardiovascular events, family history of Hypercholesterolemia and patients insensitive to statins may lower their LDL-C by approximately fifty percent with Inclisiran, which needs to be subcutaneously administered at 0 and three months, and then every six months owing to its favourable pharmacokinetics [46]. The abdomen is the recommended injection site; nevertheless, Inclisiran can also be injected to the upper arm or thigh, sparing places in which the skin is inflamed or injured. It accomplishes its maximal plasma concentration around 4 hours after dosing. Inclisiran possess half-time about 9 hours; 24 towards 48 hours after medication, it becomes undetectable in the bloodstream. Its metabolic reactions are regulated by nonspecific nucleases [47]. Inclisiran and its metabolites are primarily eliminated through urine, with biliary excretion making up an insignificant amount. Considering inclisiran's extended PCSK9 inhibition enables an annual dose schedule, it's an appropriate alternative for long-term LDL-C management [48].

Pharmacodynamics of Inclisiran

The effects of inclisiran on circulating lipoproteins are noteworthy and appear nearly maximal 90 days after the 300 mg dose is administered. These outcomes become observable 14 days after the dose is administered. Inclisiran acts for six months following two consecutive 300 mg doses on day one and day 90 and also 19% deduction in bad-C values is attained by second dose on day 90 [49]. Clinical investigations have shown that when administered at 3-month and 6-month intervals, inclisiran lowers mean LDL-C by approximately half when compared to a placebo. Long-term follow-ups indicate that the LDL-C decreasing affect remains constant, confirming the pharmacodynamic action's endurance [50].

Safety and Efficacy

Concerning individuals with elevated levels of cholesterol, safety is an important consideration in medications. The synthetic short siRNA Inclisiran, based on its chemical structure, serves as indication, possesses the ability to hybridize into the complementary mRNA of PCSK9, and may degrade PCSK9. The longer duration of biological activity and enhanced stability are credited to Inclisiran's unique structural modification. As a result of Inclisiran's distinct mode of action, the concentration of LDL-C can be considerably, effectively, and perpetually lowered by degrading both intracellular and extracellular PCSK9 protein levels. Treating hypercholesterolemia with inclisiran can lower the risk of acute vascular events all while also being safe and well-tolerated [51].

Dose and administration

Inclisiran is delivered underneath the skin about 284 mg on day 1, ninety days later, and then every six months following that. In accordance to ORION-1 trial's findings, demonstrated that after the initial two doses, bad-C levels consistently reduced by nearly fifty percent at 180 and 240 days, served as the basis for this dosing plan. With comparable outcomes, this dosage schedule has been applied to all ensuing Phase 3 trials assessing inclisiran's effectiveness. The bad-C reducing outcome lasts about the course of biannual dosage regimen; however, concentrations become undetectable 24–48 hours after treatment, with a 9-hour terminal elimination half-life [52].

CONCLUSION

Hypercholesterolemia is the main cause of atherosclerosis that results to cardiovascular diseases. Hence its management is very important that involves multiple approaches including lifestyle modifications, pharmacological interventions and in severe cases liver transplantation and gene editing. Understanding its pathogenesis in detail has led to development of targeted therapy. Traditional treatments including statins have effectively managed cholesterol levels but have shown limitations such as statin intolerance. Hence there is a need of developing novel therapies like inclisiran. A key protein involved in cholesterol regulation- PCSK9 gets targeted by a small interfering RNA (siRNA), which leads to a significant advancement in the therapy. Inclisirin enhances the liver's ability to remove LDL cholesterol from the blood by reducing PCSK9 levels. This offers sustained reduction of LDL cholesterol from the body just by 2 doses per year. The problems faced by the traditional therapies are effectively overruled by this biannual dosing regimen. Although inclisiran shows promising results in lowering LDL-C levels, certain limitations must be considered. Long-term safety and efficacy data are still limited, as most studies have follow-up periods of only a few years. The high cost of Inclisiran may also limit accessibility, particularly in low-

middle-income countries. More studies are needed to address these concerns and establish Inclisiran's long-term role in hypercholesterolemia management. There is a hope for more effective and personalised treatments with on-going research in gene therapies and new pharmacological approaches thereby improving patient outcomes and decreasing the global burden of Hypercholesterolemia.

Acknowledgements

We sincerely thank Dr. Kishore kumar for his invaluable dedication and expertise in finalizing this manuscript. His insightful suggestions were crucial. We also extend our heartfelt gratitude to Dr T. Rama Rao for his significant contributions and valuable input, which greatly supported the completion of this review.

Abbreviations

LDL – Low density lipoprotein; **VLDL**- Very low density lipoprotein; **IDL**- Intermediate lipoprotein; **HDL** – High density lipoprotein; **PCSK9**-Proprotein convertase subtilisin/Kexin type 9; **siRNA**- Small interfering RNA, **LDL-C** – Low density lipoprotein cholesterol.

Authors Contributions

Conceptualization, P. Kishore Kumar; writing-original draft preparation, Bagadam Aparna; writing-review and editing, Bagadam Aparna, Kurmapu Malikarjun Rao and Syed Mohiuddin Quadri; supervision- V. Uma Maheshwara Rao.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology. 2020 Dec 22;76(25):2982–3021.
2. Mathew CT, Singh P. Fibric Acid Antilipemic Agents [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538508/
3. Poznyak AV, Litvinova L, Poggio P, Orekhov AN, Melnichenko AA. Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis. Biomedicines. 2022 Oct 20;10(10):2639.
4. Collado A, Domingo E, Piqueras L, Sanz MJ. Primary hypercholesterolemia and development of cardiovascular disorders: Cellular and molecular mechanisms involved in low-grade systemic inflammation and endothelial dysfunction. The International Journal of Biochemistry & Cell Biology. 2021 Oct;139:106066.
5. Yu Cai Lim M, Kiat Ho H. Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia. Biochemical Pharmacology [Internet]. 2024 Feb 1;220:115985. Available from: https://www.sciencedirect.com/science/article/pii/S0006295223005786
6. Feingold KR. Introduction to Lipids and Lipoproteins. 2024 Jan 14. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 26247089.
7. Fisher E, Cohen D. Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease. 2013 Nov 12;33(04):380–8.
8. Raul-Alexandru Jigoranu, Roca M, Alexandru Dan Costache, Ovidiu Mitu, Alexandru Florinel Oancea, Radu-Ștefan Miftode, et al. Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment. Life. 2023d Jul 27;13(8):1639–9.
9. Ibrahim MA, Jialal I. Hypercholesterolemia [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020c. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459188/
10. Abifadel M, Boileau C. Genetic and molecular architecture of familial hypercholesterolemia. Journal of Internal Medicine. 2022c Oct 17;293(2):144–65.
11. Fularski P, Hajdys J, Majchrowicz G, Stabrawa M, Młynarska E, Rysz J, et al. Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy. International Journal of Molecular Sciences [Internet]. 2024 Jan 29;25(3):1637. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10855128/
12. Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024 Dec 16;
13. Zhang Y, Chen H, Liu H, Wang H, Li B, Zhang M, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Frontiers in Pharmacology. 2023 Oct 13;14.
14. Yang A, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology [Internet]. 2020 Jul 1;20(5):795–800. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1424390320301988
15. Prasad K, Mishra M. Mechanism of Hypercholesterolemia-Induced Atherosclerosis. Reviews in Cardiovascular Medicine. 2022b Jun 9;23(6):212.
16. Huff T, Boyd B, Jialal I. Physiology, Cholesterol [Internet]. Nih.gov. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470561/
17. Su L, Mittal R, Ramgobin D, Jain R, Jain R. Current Management Guidelines on Hyperlipidemia: the Silent Killer. Journal of Lipids [Internet]. 2021 Jul 31;2021(1):9883352. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363437/

18. Oommen D, Kizhakkedath P, Jawabri AA, Varghese DS, Ali BR. Proteostasis Regulation in the Endoplasmic Reticulum: An Emerging Theme in the Molecular Pathology and Therapeutic Management of Familial Hypercholesterolemia. Frontiers in Genetics. 2020b Sep 23;11.

19. Wu YX, Wang Y. [Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor]. Yi Chuan = Hereditas. 2020 Oct;42(10):965-978. DOI: 10.16288/j.yczz.20-065. PMID: 33229322.

20. Kim NT, Do DL, Nguyen MNT, Le HA, Le TT, Truong TH. Exploring LDLR-APOB Interactions in Familial Hypercholesterolemia in the Vietnamese Population: A Protein-Protein Docking Approach. Bioinformatics and Biology Insights. 2024 Jan 1;18.

21. Jiang H, Zhou Y, Nabavi SM, Sahebkar A, Little PJ, Xu S, et al. Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis. Frontiers in Cardiovascular Medicine. 2022 Jun 1;9(925923).

22. Leuti A, Fazio D, Fava M, Piccoli A, Oddi S, Maccarrone M. Bioactive lipids, inflammation and chronic diseases. Advanced Drug Delivery Reviews. 2020;159:133–69.

23. Zhang Y, Sarah, Moran AE. Genetic testing for familial hypercholesterolemia. Current opinion in lipidology. 2024b Jan 31;35(2):93–100.

24. Gibbs BB, Hivert MF, Jerome GJ, Kraus WE, Rosenkranz SK, Schorr EN, et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: Who, what, and how?: A scientific statement from the American Heart Association. Hypertension. 2021 Jun 2;78(2).

25. Muscella A, Stefàno E, Marsigliante S. The effects of exercise training on lipid metabolism and coronary heart disease. American Journal of Physiology-Heart and Circulatory Physiology [Internet]. 2020 Jul 1;319(1):H76–88. Available from: https://journals.physiology.org/doi/full/10.1152/ajpheart.00708.2019

26. Bansal AB, Cassagnol M. HMG-CoA Reductase Inhibitors. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542212/?utm_source=chatgpt.com

27. Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (Statins) and their Drug Interactions involving CYP enzymes, P-glycoprotein and OATP Transporters - An Overview. Current Drug Metabolism. 2021 Jan 14;22.

28. Susekov AV. [Lipid-lowering Eeficacy and Safety of High Doses of Atorvastatin and Rosuvastatin]. Kardiologiia [Internet]. 2023 Feb 1 [cited 2023 Oct 22];63(2):59–67. Available from: https://europepmc.org/article/med/36880145

29. Feng Y, Li Q, Ou G, Yang M, Du L. Bile acid sequestrants: a review of mechanism and design. Journal of Pharmacy and Pharmacology [Internet]. 2021 Apr 22;73(7):855–61. Available from: https://academic.oup.com/jpp/article-abstract/73/7/855/6245995?redirectedFrom=fulltext

30. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. International Journal of Clinical Practice [Internet]. 2009 Sep 1;63(9):1369–77. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779993/

31. Carlson, L. A. "Nicotinic Acid: The Broad-Spectrum Lipid Drug. A 50th Anniversary Review." *Journal of Internal Medicine*, vol. 258, no. 2, 1 Aug. 2005, pp. 94–114, pubmed.ncbi.nlm.nih.gov/16018787/, https://doi.org/10.1111/j.1365-2796.2005.01528.x. Accessed 5 Mar. 2021.

32. Mathew CT, Singh P. Fibric Acid Antilipemic Agents [Internet]. Nih.gov. StatPearls Publishing; 2023 [cited 2025 Mar 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538508/?utm_source=chatgpt.com

33. Mathew CT, Singh P. Fibric Acid Antilipemic Agents. [Updated 2023 Feb 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538508/

34. Makhmudova U, Schulze PC, Davis HR, Weingärtner O. Lipid lowering in patients 75 years and older. World Journal of Cardiology [Internet]. 2021 Oct 26 [cited 2023 Jul 1];13(10):526–32. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554361/

35. Mansfield BS, Adriano Dello-Iacono, Raal FJ. Ezetimibe in the management of homozygous familial hypercholesterolaemia. Journal of clinical lipidology. 2024 Nov 1;

36. Al Dubayee M, Kayikcioglu M, van Lennep JR, Hergli N, Mata P. Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases. Advances in Therapy. 2022 Apr 26;39(6):3042–57.

37. Hadipour K, Asadishad T, Mahya L, Mohammadhassan R, Rahbar A, Goudarziasl F. A Comparative Review on Genome Editing Approaches. Biointerface Research in Applied Chemistry [Internet]. 2022b [cited 2025 Mar 23];13(6):567. Available from: https://biointerfaceresearch.com/wp-content/uploads/2023/03/BRIAC136.567.pdf

38. Hoekstra M, Miranda Van Eck. Gene Editing for the Treatment of Hypercholesterolemia. Current Atherosclerosis Reports. 2024 Mar 18;

39. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis [Internet]. 2010 Feb 1 [cited 2023 Oct 16];208(2):317–21. Available from: https://pubmed.ncbi.nlm.nih.gov/19589528/

40. Zehra Narlı Özdemir, Uğur Şahin, Yasin Yıldırım, Cansın Tulunay Kaya, Osman İlhan. Lipoprotein apheresis efficacy and challenges: single center experience. Hematology, Transfusion and Cell Therapy. 2022 Jan 1;44(1):56–62.

41. Mohamed F, Brett Stephen Mansfield, Raal FJ. Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol. Journal of Clinical Medicine. 2023 Aug 2;12(15):5082–2.

42. Ray D, Salvatore M, Bhattacharyya R, Wang L, Du J, Mohammed S, Purkayastha S, Halder A, Rix A, Barker D, Kleinsasser M, Zhou Y, Bose D, Song P, Banerjee M, Baladandayuthapani V, Ghosh P, Mukherjee B. Predictions, role of interventions and effects of a historic national lockdown in India's response to the COVID-19 pandemic:

data science call to arms. Harv Data Sci Rev. 2020;2020(Suppl 1):10.1162/99608f92.60e08ed5. doi: 10.1162/99608f92.60e08ed5. Epub 2020 Jun 9. PMID: 32607504; PMCID: PMC7326342.

43. Dyrbuś, Krzysztof, et al. "Inclisiran—New Hope in the Management of Lipid Disorders?" *Journal of Clinical Lipidology*, vol. 14, no. 1, Jan. 2020, pp. 16–27, https://doi.org/10.1016/j.jacl.2019.11.001.

44. Wołowiec Ł, Osiak J, Wołowiec A, Wijata A, Grześk E, Kozakiewicz M, et al. Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9. Pharmaceutics [Internet]. 2023 Feb 1;15(2):323. Available from: https://www.mdpi.com/1999-4923/15/2/323

45. Tomlinson B, Chow E, Chan P, Lam CWK. An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. Expert Opinion on Drug Metabolism & Toxicology. 2022 Jan 20;1–9.

46. Merćep I, Friščić N, Strikić D, Reiner Ž. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review. Tomlinson B, editor. Cardiovascular Therapeutics. 2022 Feb 10;2022:1–6.

47. Dec A, Niemiec A, Wojciechowska E, Maligłówka M, Bułdak Ł, Bołdys A, et al. Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy. International Journal of Molecular Sciences [Internet]. 2023 Apr 6;24(7):6858. Available from: https://pubmed.ncbi.nlm.nih.gov/37047830/

48. Hu J, Lei H, Chen J, Liu L, Gui Y, Sun K, et al. Aerobic exercise alleviates statin-induced PCSK9 upregulation by increasing epoxyeicosatrienoic acid levels through the FoxO3a–Sirt6 axis. Journal of Sport and Health Science. 2025 Dec;14:101007.

49. Mikhail N. Update on Inclisiran for Treatment of Hypercholesterolemia. Journal of Diabetes Research Reviews & Reports. 2020 Jun 30;1–3.

50. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 2020 Apr 16;382(16):1520–30.

51. Li J, Lei X, Li Z, Yang X. Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews. Medicine. 2023 Jan 20;102(3):e32728.

52. Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease. Vascular Health and Risk Management [Internet]. 2023;19:421–31. Available from: https://pubmed.ncbi.nlm.nih.gov/37434791/